News
A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the ...
A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...
1d
Asian News International on MSNAbu Dhabi Public Health Centre, AstraZeneca forge strategic partnershipUse precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...
Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing facility will be ...
A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ ...
AstraZeneca Plc lost its crown as the UK’s most valuable listed company after US President Donald Trump’s plans to lower drug ...
Explore more
8don MSN
AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ...
2d
Business and Financial Times on MSNTrust Specialist Hospital, AstraZeneca push asthma breakthrough with symbicort accessBy Sandra Agyeiwaa OTOO Trust Specialists Hospital, in partnership with AstraZeneca, has marked World Asthma Day 2025 with a ...
AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that just like Europe has stepped up its defence spending ...
The facility, which will produce cell therapies used to treat cancer and auto immune diseases, creates 150 jobs for highly ...
AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non-muscle | ...
8d
Pharmaceutical Technology on MSNEC approves AstraZeneca’s Calquence combo to treat MCLThe European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results